WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Slides:

Advertisements

Similar presentations

Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.

Advertisements

WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.

Dr Tin Tin Sint Department of HIV/AIDS World Health Organization

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

2nd Line ART Considerations for Resource-Limited Settings

P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda.

Terapia ARV u chorych z koinfekcją HIV/HBV/HCV – czy istnieją preferencyjne schematy ARV. Marek Beniowski.

Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 HIV Treatment for Adults and Adolescents Stefano Vella MD Istituto Superiore di Sanità -

Country Experience Informing Feasibility Option B+ (Malawi) Tenofovir phase in 1 st line( Zambia) d4T phase out in HIV programmes Raising CD4 threshold.

ART stock-outs Francois Venter Wits Reproductive Health & HIV Institute.

Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations WHO 2013 ARV Guidelines Launch Dr. Meg Doherty, WHO, Geneva.

ART in Resource-limited settings : Progress and Challenges Dr. B. B. Rewari MD,FRCP,FICP,FIACM,FGSI,FIAMS,FIMSA, NPO (ART) India 21 st July 2014, Adult.

Michelle Moorhouse 26 Mar 2015

Post Exposure Prophylaxis for HIV

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A OREY.

The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.

Medicines Patent Pool – Strictly Confidential, Not for Circulation Licensing Technology and Intellectual Property for the Development of Paediatric Formulations.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 TRACK B RAPPORTEUR REPORT Jürgen Rockstroh on behalf of… Sharon Walmsley Jintanat Ananworanich.

Excellent healthcare – locally delivered OVERVIEW OF CLINICAL RECOMMENDATIONS FOR ADULTS, PREGNANT WOMEN AND CHILDREN OVERVIEW OF CLINICAL RECOMMENDATIONS.

HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Crossroads Hotel 7 th January  All adolescents & adults with HIV infection & CD4 counts less than/equal to 350 cells/mm3, including pregnant women,

ICASA IAS Scaling up Treatment Delivery Programmes: Issues, Challenges & Best Practices Siobhan Crowley HIV Department WHO Geneva.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.

Prevention and Care Dr S Charalambous WHO guidelines.

Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.

Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.

SPECIAL CONSIDERATIONS August

Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.

HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Accumulation of Protease Mutations Among Patients on Non-Suppressive 2 nd -Line ART in Nigeria H. Rawizza, B. Chaplin, S. Meloni, P. Okonkwo, P. Kanki.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.

Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,

Optimizing the Paediatric ARV Pipeline Nandita Sugandhi Clinton Health Access Initiative &IATT CSWG ICASA 2015, Harare Zimbabwe November 30, 2015.

WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.

The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)

Switch to PI/r monotherapy

Antiretroviral Therapy (ART)

How differentiated care supports “Tx all” and Dr

HIV Treatment for Adults and Adolescents

WHO perspectives on dolutegravir

2017 Key Considerations for adolescents and children & Key populations

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

The role of Dolutegravir in first-line regimens

Closing the Treatment Gap of Children Living with HIV

Rationale: 2nd Line Regimens in Adults

Understanding the unmet medical needs with current ART

Martina Penazzato MD, PhD Paediatric lead, HIV Department

Marco Vitoria HIV Department Geneva

The Brazilian Experience

Cases from the Clinic(ians): Case-based Panel Discussion

Charles Gilks HIV Department, WHO

Comparison of PI vs PI ATV vs ATV/r BMS 089

Comparison of PI vs PI ATV vs ATV/r BMS 089

CASO CLINICO Il paziente naϊve con resistenze al basale.

Comparison of PI vs PI ATV vs ATV/r BMS 089

Multi-disease diagnostic integration

Target-Setting, Impact and Resource Needs

Presentation transcript:

WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization

WHO ART guidelines evolution Topic When to start CD4 ≤200 - Consider CD4 ≤ 350 for TB CD4 ≤ 350 -Irrespective CD4 for TB and HBV CD4 ≤ 500 -Irrespective CD4 for TB, HBV, PW and SDC - CD4 ≤ 350 as priority 1 st Line 8 options - AZT preferred 4 options - AZT preferred 8 options - AZT or TDFpreferred - d4T dose reduction 6 options &FDCs - AZT or TDF preferred - d4T phase out 2 options & FDCs -TDF and EFV preferred across all populations 2 nd Line Boosted and non- boosted PIs Boosted PIs -IDV/r LPV/r, SQV/r Boosted PI - ATV/r, DRV/r, FPV/r LPV/r, SQV/r Boosted PI - Heat stable FDC: ATV/r, LPV/r Boosted PIs -Heat stable FDC: ATV/r, LPV/r 3 rd Line None DRV/r, RAL, ETV Viral Load Testing No (Desirable) Yes (Tertiary centers) Yes (Phase in) Yes (preferred) Vitoria M, et al, Current Opinions HIV/AIDS, 2013

WHO ART guidelines evolution Topic When to start CD4 ≤200 - Consider CD4 ≤ 350 for TB CD4 ≤ 350 -Irrespective CD4 for TB and HBV CD4 ≤ 500 -Irrespective CD4 for TB, HBV, PW and SDC - CD4 ≤ 350 as priority 1 st Line 8 options - AZT preferred 4 options - AZT preferred 8 options - AZT or TDFpreferred - d4T dose reduction 6 options &FDCs - AZT or TDF preferred - d4T phase out 2 options & FDCs -TDF and EFV preferred across all populations 2 nd Line Boosted and non- boosted PIs Boosted PIs -IDV/r LPV/r, SQV/r Boosted PI - ATV/r, DRV/r, FPV/r LPV/r, SQV/r Boosted PI - Heat stable FDC: ATV/r, LPV/r Boosted PIs -Heat stable FDC: ATV/r, LPV/r 3 rd Line None DRV/r, RAL, ETV Viral Load Testing No (Desirable) Yes (Tertiary centers) Yes (Phase in approach) Yes (preferred for monitoring, use of PoC, DBS) Earlier initiation Simpler treatment Less toxic, more robust regimens Better monitoring Vitoria M, et al, Current Opinions HIV/AIDS, 2013

Recommendations on ART Monitoring  Viral load is recommended as the preferred monitoring approach to diagnose and confirm ARV treatment failure ( strong recommendation, low-quality evidence )  If viral load is not routinely available, CD4 count and clinical monitoring should be used to diagnose treatment failure ( strong recommendation, moderate-quality evidence )  Definition of virological failure: plasma viral load above 1000 copies/ml based on two consecutive viral load measurements after 3 months, with adherence support (6 months post ART)  Higher threshold for DBS and point-of-care technologies

Implementation considerations ART access should be the first priority: Lack of laboratory tests for monitoring treatment response should not be a barrier to initiating ART Prioritization: If viral load availability is limited, it should be phased in using a targeted approach to confirm treatment failure. This may be particularly relevant in populations receiving ARVs to reduce HIV transmission, such as pregnant and breastfeeding women and in sero- discordant couples.

Implementation considerations Feasibility of phasing in VL capacity (DBS) PoC viral load on horizon Enables monitoring of treatment for prevention Equity Cost-effectiveness influenced by monitoring approach (frequency, additive or as replacement to CD4)